Search Results
May 22, 2026, 21:12 ET Lupin erhält Zulassung in China für Oseltamivirphosphat-Suspension zum Einnehmen
Oseltamivirphosphat-Suspension zum Einnehmen, 6 mg/ml, wird eingeführt und vermarktet, um den Zugang zu erweitern, insbesondere für die pädiatrische Anwendung. Damit baut Lupin seine globale Präsenz aus
More news about: Lupin Limited
May 22, 2026, 21:10 ET Lupin reçoit l'approbation de la Chine pour la suspension orale de phosphate d'oseltamivir
Le phosphate d'oseltamivir pour suspension orale, 6 mg/mL, sera lancé et commercialisé afin d'en élargir l'accès, en particulier pour un usage pédiatrique. Lupin renforce ainsi sa présence mondiale et son engagement
More news about: Lupin Limited
May 22, 2026, 12:13 ET Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
suspension, 6 mg/mL will be launched and commercialized to expand access, particularly for pediatric use. This expands Lupin's global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need.Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL
More news about: Lupin Pharmaceuticals, Inc.
May 22, 2026, 10:00 ET Lupin recibe la aprobación en China para la suspensión oral de fosfato de oseltamivir
oseltamivir de 6 mg/ml para ampliar el acceso, especialmente para uso pediátrico. Esto expande la presencia global de Lupin y reafirma su compromiso de brindar medicamentos asequibles y de alta calidad a pacientes y niños que los necesitan.El fosfato de oseltamivir para suspensión oral, 6 mg (base)/mL,
More news about: Lupin Limited
May 22, 2026, 08:00 ET AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
aged 3 years and older. In adults and adolescents aged 12 years and older, or children weighing at least 45 kg, the recommended dose is three 100 mg/40 mg tablets once daily with food. In children aged 3 years to less than 12 years and weighing 12 kg to less than 45 kg, MAVIRET is available as coated
More news about: AbbVie
May 22, 2026, 07:06 ET Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
suspension, 6 mg/mL will be launched and commercialized to expand access, particularly for paediatric use. This expands Lupin's global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need.Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL
More news about: Lupin Limited
May 22, 2026, 07:00 ET Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
suspension, 6 mg/mL will be launched and commercialized to expand access, particularly for paediatric use. This expands Lupin's global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need.Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL
More news about: Lupin Limited
May 22, 2026, 07:00 ET BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
(including U87-MG and SNB-19) and was able to penetrate the brain efficiently after oral dosing, with brain exposure corresponding to 68-85% of plasma levels in mice. Safety studies in animals indicated that GLIX1 is well-tolerated even at the highest feasible doses tested: 2000mg/kg in rats and 1000mg/kg in
More news about: BioLineRx Ltd.; Hemispherian AS
May 22, 2026, 06:02 ET 14 Press Releases You Need to See This Week
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialIn TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric
More news about: PR Newswire
May 22, 2026, 04:45 ET Navamedic launches Virono®- the first single-dose over-the-counter cold sore tablet
Netherlands4.Expanding Navamedic's Consumer Health portfolioVirono® is a prescription-free medicine containing 50 mg aciclovir in a mucoadhesive buccal tablet designed for local treatment of recurrent cold sores. The tablet is applied once per outbreak at the first
More news about: Navamedic ASA
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
combination dosing regimens were compared in the study: 3→1.5 mg/kg dose group (3 mg/kg + PDC in cycle 1, followed by 1.5 mg/kg Q3W + PDC); 1.5 mg/kg dose group (1.5 mg/kg Q3W + PDC); 3 mg/kg dose group (3 mg/kg Q3W + PDC). 2) Study Design and Baseline Characteristics:
More news about: Innovent Biologics
May 21, 2026, 20:00 ET 2026 ASCO | 科倫博泰2項 註冊研究入選2026 ASCO非小細胞肺癌口頭報告專場
(摘要編號#8506，肺癌—轉移性非小細胞)研究共納入413例既往未接受系統治療的無表皮生長因數受體(EGFR)/間變性淋巴瘤激酶(ALK)突變且程式性細胞死亡配體1 (PD-L1)表達陽性(定義為腫瘤細胞陽性比例分數(TPS)≥1%)的局部晚期或轉移性NSCLC患者，覆蓋鱗狀和非鱗狀組織學類型，按1:1隨機分配接受蘆康沙妥珠單抗(sac-TMT) (4 mg/kg，Q2W)聯合帕博利珠單抗(400 mg，Q6W)或帕博利珠單抗單藥(400 mg, Q6W)治療。研究主要終點為經盲態獨立中心評估(BICR) 評估的無進展生存期(PFS)，關鍵次要終點為總生存期(OS)。截至2025年9月29日，中位隨訪時間為10.5個月。研究結果顯示：PFS顯著改善：經BICR評估，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗組較帕博利珠單抗組顯著延長PFS，中位PFS為尚未達到(NR)
More news about: 科倫博泰
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
≥1%), covering both squamous and non‑squamous histologies, were enrolled and randomized (1:1) to receive sac-TMT (4mg/kg Q2W) plus pembrolizumab (400mg Q6W) or pembrolizumab monotherapy (400mg Q6W). The primary endpoint was progression‑free survival (PFS) assessed by blinded independent central review (BICR),
More news about: Kelun-Biotech
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Among the 58 patients with EGFR wild-type adenoNSCLC, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 25 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg dose group, the median PFS reached 4.2 (95%CI 3.0, 7.0) months, and the median OS achieved 15.2
More news about: Innovent Biologics
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
NCT05599984) of ABBV-706 (SEZ6-directed ADC) in the monotherapy cohort (n=17), SCLC patients receiving ABBV-706 at the recommended Phase 3 dose of 1.8 mg/kg as a second-line therapy achieved an objective response rate (ORR) of 82%— promising data in a disease where prognosis remains poor. The safety profile
More news about: AbbVie
May 21, 2026, 17:23 ET Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
ARROS-1 clinical trial as of a data cutoff date of September 22, 2025. The majority (12/15) of patients received the recommended Phase 2 dose of 100 mg once daily. Patients were refractory to standard-of-care therapies (60%, 9/15) or were previously treated with a ROS1 TKI (40%, 6/15), and 73% (11/15)
More news about: Nuvalent, Inc.
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
leukocytosis.If differentiation syndrome is suspected, temporarily withhold REZLIDHIA and initiate systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) for a minimum of 3 days and until resolution of signs and symptoms. If concomitant leukocytosis is observed, initiate treatment with
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
expected to be above the anticipated minimally effective dose.HWK-007 completed the first dose cohort at 2 mg/kg and is enrolling the second cohort at 4 mg/kg. HWK‑007 is being evaluated in patients with non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian
More news about: Whitehawk Therapeutics, Inc.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Retevmo-related adverse reactions in patients with hepatic impairment.Retevmo (selpercatinib) is available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets.SE HCP ISI LA_NOV2025Please see full
More news about: Eli Lilly and Company
May 21, 2026, 17:00 ET Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
the trial, visit clinicaltrials.gov (NCT05377996).VORANIGO IMPORTANT SAFETY INFORMATIONWhat is VORANIGO?VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma
More news about: Servier Pharmaceuticals
May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
ORR was 73%, with 7% of patients achieving a complete response and 66% achieving a partial response, and the disease control rate was 91%. In the 60 mg cohort (n=29), the confirmed ORR was 76% (10% complete response, 66% partial response).5Median duration of response (mDoR) and median progression‑free survival (PFS)
More news about: Boehringer Ingelheim
May 21, 2026, 16:54 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
met the primary efficacy endpoint, defined as the proportion of patients achieving a serum uric acid (sUA) level <6 mg/dL at month 6 (75 mg: 69.2% vs 8.1%; p<0.0001; 50 mg: 56.6% vs 8.1%; p<0.0001). The safety profile was consistent with previous studies. Detailed results are expected
More news about: Swedish Orphan Biotrauma AB
May 21, 2026, 16:51 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
met the primary efficacy endpoint, defined as the proportion of patients achieving a serum uric acid (sUA) level <6 mg/dL at month 6 (75 mg: 69.2% vs 8.1%; p<0.0001; 50 mg: 56.6% vs 8.1%; p<0.0001). The safety profile was consistent with previous studies. Detailed results are expected
More news about: Swedish Orphan Biotrauma AB
May 21, 2026, 14:03 ET New research shows how snacking on almonds improves diets
provides 6g of protein, 4g of fiber, 13g of unsaturated fat, only 1g of saturated fat, and 15 essential nutrients, including 77 mg magnesium (20% DV), 210 mg potassium (4% DV), and 7.3 mg vitamin E (50% DV).Like all research, this study had limitations. Dietary intake was based on self-reported data,
More news about: Almond Board of California
May 21, 2026, 10:00 ET Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
academic centers in the US, EU, China, and Australia.Participants are randomized 1:1 to receive once-daily oral rocbrutinib (200 mg) or pirtobrutinib (200 mg). The primary endpoint is progression-free survival (PFS), and secondary endpoints include overall survival (OS, key secondary endpoint),
More news about: Lupeng Pharmaceutical Ltd